Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review
Introduction Infant immunization programs using pneumococcal conjugate vaccines (PCVs) have reduced the rates of pneumococcal disease through direct vaccine-induced protection in vaccinated children and through indirect protection in non-vaccinated children and adults.Areas covered This review summa...
Saved in:
| Main Authors: | Elmira Flem, Celine Mouawad, Arto A. Palmu, Heather Platt, Kelly D. Johnson, E. David McIntosh, Jacobo Abadi, Ulrike K. Buchwald, Kristen Feemster |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2416229 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024-12-01) -
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
by: Shigeki Nakamura, et al.
Published: (2024-12-01) -
IAPSM’s Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India
by: Chythra R. Rao, et al.
Published: (2024-12-01) -
The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US
by: Aleksandar Ilic, et al.
Published: (2024-11-01) -
High prevalence of 19A pneumococcal serotype carriage during the COVID-19 pandemic in Brazil
by: Muriel Primon-Barros, et al.
Published: (2024-11-01)